Club Phase 1, a group representing early clinical development stakeholders in France, held their 16th Annual Meeting in Paris on 22nd March.
Topics ranged from dealing with immunogenicity to Drug Drug Interactions and a session led by a Biotrial representative on the Bial 10-2474 incident.
You can find the presentations at this link.
Club Phase 1 is a founding member of EUFEMED (the European Federation for Exploratory Medicines Development) that was formally incorporated in May 2015 and also includes AHPPI, BAPU, AGAH – the British, Belgian and German professional member associations specialising in human pharmacology.
Written by Nathan McCavery, Commercial Manager at BioKinetic Europe. Nathan is a member of the AHPPI Organising Committee.